Accessibility Menu
Femasys logo

Femasys(NASDAQ) FEMY

Market Cap$6.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-99%
5 Year-98%
1 Year-85%
1 Month-36%
$2.31
-1.70%
-0.04Today
After hours$2.36+$0.05 (+2.17%)
Femasys last closing stock price
MetricPriceDate
Last closeUSD 2.292026-08-13
Femasys stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-22.37%USD 2.952026-08-06
1 month-36.39%USD 3.602026-07-14
3 month-67.89%USD 7.132026-05-15
Year to date-80.13%USD 11.522025-12-31
1 year-85.06%USD 15.332025-08-13
3 year-73%USD 8.482023-08-14
5 year-98.38%USD 141.002021-08-13
Since inception-99.02%USD 240.002021-06-18

Femasys Financials at a Glance

Market Cap

$6.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$2.38M

Net Income (TTM)

-$12.40M

EPS (TTM)

-$6.46

P/E Ratio

-0.35

Dividend

$0.00

Beta (Volatility)

1.03 (Average)

Price

$2.31

Volume

154,879.759

Open

$2.37

Previous Close

$2.29

Daily Range

$2.22 - $2.45

52-Week Range

$2.19 - $22.20

Estimated Earnings Date

Aug 12, 2026

FEMY News

Foolcom-Featured.png

Femasys Revenue Jumps 85 Percent in Q2

Motley Fool Markets TeamAug 8, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Femasys

Femasys develops medical devices for women’s reproductive health needs. Its products help with permanent birth control and infertility treatment. These solutions offer non-surgical options for patients and healthcare providers.

Products and Services

  • Permanent Birth Control: FemBloc blocks fallopian tubes without surgery; FemChec confirms the procedure’s success. (FemBloc: 35% of 2025 revenue)
  • Infertility Solutions: FemaSeed delivers sperm directly to the fallopian tube; FemSperm assists with sperm preparation; FemVue checks if tubes are open.
  • Cancer Diagnostics: FemCerv collects cervical tissue for cancer testing; FemEMB is in development for uterine cancer detection.
  • International Distribution: Products sold in the U.S. Europe, Canada, Japan, and other regions through direct sales and distributors.

Growth and Expansion

  • Launched FemBloc in 2025, expanding into permanent birth control market.
  • Secured regulatory approvals for FemBloc in the EU, UK, and New Zealand in 2025.
  • Formed partnerships with Boston IVF, HRC Fertility, and CNY Fertility to reach more infertility clinics.
  • Expanded international distribution with Kebomed Europe AG (France), Comercial Medico Quirugica SA (Spain), and Bayer Yakuhin (Japan).
  • Increased U.S. sales force to 10 representatives for infertility products in 2025.

What Makes Femasys Stand Out

Femasys offers non-surgical, in-office solutions for birth control and infertility, filling gaps left by traditional methods. The company manages its own manufacturing and holds 228 global patents. Its products reach both U.S. and international markets through direct and distributor sales channels.

Five Things You Need to Know

  • Revenue was $2.29 million in 2025, up 40.8% from 2024.
  • International sales made up 39.2% of 2025 revenue.
  • FemBloc contributed $810,000 in 2025, after commercial launch.
  • Net loss was $18.6 million in 2025, slightly improved from 2024.
  • Cash and equivalents were $9.27 million at December 31, 2025.

Bottom Line

Femasys has grown by launching new products and expanding globally. The company focuses on non-surgical women’s health solutions but faces ongoing financial and operational challenges.

AI Generated • Apr 16, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

54

CEO

Kathy Lee-Sepsick, MBA

Website

www.femasys.com

Headquarters

Suwanee, GA 30024, US

FEMY Financials

Key Financial Metrics (TTM)

Gross Margin

53.12%

Operating Margin

-687.93%

Net Income Margin

-521.78%

Return on Equity

-258.08%

Return on Capital

-166.46%

Return on Assets

-75.19%

Earnings Yield

-2.86%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$6.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

3.02M

Volume

154.88K

Avg. Volume

109.05K

Financials (TTM)

Gross Profit

$1.26M

Operating Income

-$16.35M

EBITDA

-$9.44M

Operating Cash Flow

-$18.07M

Capital Expenditure

-$553.03K

Free Cash Flow

-$18.62M

Cash & ST Invst.

$5.39M

Total Debt

$4.73M

Femasys Performance Analysis

Femasys annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 1,206,2182.2%
20232023-12-31USD 1,071,970-11.1%
20242024-12-31USD 1,629,10852.0%
20252025-12-31USD 2,293,31340.8%
Femasys sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3019.9%
Q32025-09-3078.2%
Q42025-12-3111.5%
Q12026-03-31-47.8%
Femasys annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -19.3151.2%
20232023-12-31USD -18.52-4.1%
20242024-12-31USD -16.90-8.8%
20252025-12-31USD -9.42-44.3%
Femasys sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3030.4%
Q32025-09-3037.5%
Q42025-12-3133.7%
Q12026-03-31106.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$424.89K

+24.5%

Gross Profit

$65.83K

-70.6%

Gross Margin

15.49%

N/A

Market Cap

$6.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$130.47K

N/A

Employees

53

N/A

Net Income

$328.65K

+105.6%

EBITDA

$1.22M

+123.4%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$5.39M

+41.0%

Total Debt

$4.73M

-38.3%

Accounts Receivable

$172.26K

-26.3%

Inventory

$6.11M

+58.1%

Long Term Debt

$4.25M

+205.0%

Short Term Debt

$480.29K

-92.3%

Return on Assets

-75.19%

N/A

Return on Invested Capital

-1.23%

N/A

Free Cash Flow

-$4.22M

+13.1%

Operating Cash Flow

-$4.14M

+13.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PCSAProcessa Pharmaceuticals, Inc.
$2.50-2.34%
VVOSVivos Therapeutics, Inc.
$0.31+6.75%
CRISCuris, Inc.
$1.87+11.98%
AIMDAinos, Inc.
$1.44-3.36%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$8.91-0.09%
SMCISuper Micro Computer
$39.16+0.04%
SPCXSpace Exploration Technologies
$141.29-0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.64+0.07%

Questions About FEMY

What is the current price of Femasys?

Femasys is trading at $2.29 per share.

What is the 52-week range for Femasys?

Over the past 52 weeks, Femasys has traded between $2.19 and $22.20.

How much debt does Femasys have?

As of the most recent reporting period, Femasys reported total debt of $4.73M.

How much cash does Femasys have on hand?

Femasys reported $5.39M in cash and cash equivalents in its most recent financial results.

What is Femasys’s dividend yield?

Femasys does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services